Thomas James Lynch, MD

Richard Sackler and Jonathan Sackler Professor of Medicine (Medical Oncology)

Research Organizations

Medical Oncology: Subset Medical Oncology Faculty

Research Summary

Dr. Lynch has made important contributions to developmental therapeutics for lung cancer and has worked to define the optimal treatment for patients with lung cancer. He pioneered the use of molecular testing for mutations in the epidermal growth factor receptor (EGFR) gene to select patients who can benefit from targeted lung cancer therapies.

Selected Publications

  • Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko
  • Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, C
  • Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer. Politi K, Lynch TJ. Clin Cancer Res. 2012 Mar 15;18(6):1490-2.
  • Unmet challenges in the use of novel agents in locally advanced non-small-cell lung cancer. Decker RH, Lynch TJ. J Clin Oncol. 2012 Feb 20;30(6):582-4.
  • Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. Heist RS, Fain J, Chinnasami B, Khan W, Molina JR, Sequist LV, Temel JS, Fidias P, Brainerd V, Leopold L, Lynch TJ. J Thorac Oncol. 2010 Oct;5(10):1637-43.
  • Early palliative care for patients with metastatic non-small-cell lung cancer. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ. N Engl J Med. 2010 Aug 19;363(8):733
  • Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil
  • Lennes IT, Lynch TJ. Quality indicators in cancer care: development and implementation for improved health outcomes in non-small-cell lung cancer. Clin Lung Cancer. 2009 Sep;10(5):341-6.
  • Pao W, Kris MG, Iafrate AJ, Ladanyi M, Jänne PA, Wistuba II, Miake-Lye R, Herbst RS, Carbone DP, Johnson BE, Lynch TJ. Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res. 2009 Sep 1;15(17):5317-22. Epub 2009 Aug 25.

Edit this profile

Contact Info

Thomas James Lynch, MD
Patient Care Location
Smilow Cancer Hospital at Yale-New HavenSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste North Pavilion 4

New Haven, CT 06511
Mailing Address
PO Box 208028
333 Cedar Street, WWW 205

New Haven, CT 06520-8028